stanolone Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
STANOLONE, also known as dihydrotestosterone, is a potent androgenic metabolite of testosterone and anabolic agent for systemic use. It may be used as a replacement of male sex steroids in men who have androgen deficiency, for example as a result of the loss of both testes, and also the treatment of certain rare forms of aplastic anemia which are or may be responsive to anabolic androgens.   NCATS

Chemistry

  • SMILES: C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
  • InChIKey: NVKAWKQGWWIWPM-ABEVXSGRSA-N
  • Mol. Mass: 290.4403
  • ALogP: 3.96
  • ChEMBL Molecule:
    stanolone  
More Chemistry

Pharmacology

Alternative names

17beta-hydroxy-5alpha-androstan-3-one | 17beta-hydroxy-5alpha-androstane-3-one | 17beta-hydroxyandrostan-3-one | 17β-hydroxy-3-oxo-5α-androstanone | 17β-hydroxy-5α-androstan-3-one | 18f dihydrotestosterone | 18f dihydro-testosterone | 4-dihydrotestosterone | 5alpha-dihydrotestosterone | 5α-dht | androlone | androstanolone | dht | dihydrotestosteron | dihydrotestosterone | dihydrotestostérone | neodrol | stanolone

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (1)


 

Anemia

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Healthy Volunteers (Phase 1/Phase 2)

Hypogonadism (Phase 2)

Prostatic Neoplasms (Phase 1)

Testosterone (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue